{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:18:10Z","timestamp":1790673490249,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425003"],"award-info":[{"award-number":["82425003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350103"],"award-info":[{"award-number":["82350103"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330005"],"award-info":[{"award-number":["82330005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Hubei Province Department of Science and Technology","doi-asserted-by":"publisher","award":["2023BCB019"],"award-info":[{"award-number":["2023BCB019"]}],"id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104969","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:21:51Z","timestamp":1760001711000},"page":"104969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"216","author":[{"given":"Zhihan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2025.104969_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jtct.2025.01.001","article-title":"Reduced chimeric antigen receptor t cell expansion postinfusion is associated with poor survival in patients with large b cell lymphoma after two or more therapies","volume":"31","author":"Abadir","year":"2025","journal-title":"Transplant. Cell. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large b cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S myeloma immunotherapy consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104969_bib4","first-page":"177","article-title":"IFN-\u03b3 +874 A>T (rs2430561) gene polymorphism and risk of pulmonary tuberculosis: a meta-analysis","volume":"17","author":"Areeshi","year":"2021"},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104969_bib5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-Cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104969_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00277-021-04749-9","article-title":"Polatuzumab-based regimen or CAR t cell for patients with refractory\/relapsed DLBCL-a matched cohort analysis","volume":"101","author":"Avivi","year":"2022","journal-title":"Ann. hematlogy"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104969_bib7","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104969_bib8","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1182\/bloodadvances.2023010336","article-title":"Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA\/DRST study","volume":"7","author":"Ayuk","year":"2023","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104969_bib9","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR t cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104969_bib10","first-page":"988","article-title":"Anti-CD19 CAR-T cell therapy in elderly patients: multicentric Real-World experience from GETH-TC\/GELTAMO","volume":"30","author":"Bail\u00e9n","year":"2024","journal-title":"Transplant. Cel. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104969_bib12","first-page":"6207","article-title":"Impact of allogeneic stem cell transplant on safety and outcomes of chimeric antigen receptor t cell (CAR-T) therapy in patients with multiple myeloma (MM)","volume":"13","author":"Bangolo","year":"2024","journal-title":"J. Clin."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104969_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jtct.2023.08.026","article-title":"Impact of SCHOLAR-1 criteria on chimeric antigen receptor t cell therapy efficacy in aggressive b lymphoma: a real-world GELTAMO\/GETH study","volume":"29","author":"Bastos-Oreiro","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2025.104969_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.855730","article-title":"Best treatment option for patients with refractory aggressive B-Cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO\/GETH spanish groups","volume":"13","author":"Bastos-Oreiro","year":"2022","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104969_bib15","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/bloodadvances.2024012928","article-title":"Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas","volume":"8","author":"Bender","year":"2024","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104969_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clml.2022.12.015","article-title":"CAR T-Cells for the treatment of refractory or relapsed large B-Cell lymphoma: a single-center retrospective Canadian study","volume":"23","author":"Benoit","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10297","key":"10.1016\/j.critrevonc.2025.104969_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-lbel study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104969_bib19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/17843286.2024.2399365","article-title":"Single center, real-world retrospective study of CAR-T cell therapy for relapsed\/refractory large B-cell lymphoma beyond second line: five-year results at the university hospitals leuven","volume":"79","author":"Brijs","year":"2024","journal-title":"Acta Clin. Belg."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104969_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR t cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104969_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000907","article-title":"Inferior outcomes of EU versus US patients treated with CD19 CAR-T for Relapsed\/Refractory lare B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use","volume":"7","author":"Bucklein","year":"2023","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104969_bib22","first-page":"1158","volume":"185","author":"Burkhardt","year":"2019","journal-title":"Lymphoblastic Lymphoma Child. Adolesc. Rev. Curr. Chall. Future Oppor."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104969_bib23","first-page":"124","article-title":"Effectiveness and safety of CAR-T cells therapies: real life analysis. [Italian]","volume":"38","author":"Calcagno","year":"2024","journal-title":"G. Ital. di Farm. Clin."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104969_bib24","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.3390\/cancers13194789","article-title":"Real world evidence of CAR T-Cell therapies for the treatment of relapsed\/refractory B-Cell Non-Hodgkin lymphoma: a monocentric experience","volume":"13","author":"Casadei","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104969_bib25","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1182\/bloodadvances.2024013393","article-title":"CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas","volume":"8","author":"Cederquist","year":"2024","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104969_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/10428194.2023.2285236","article-title":"Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the mayo clinic experience","volume":"65","author":"Chohan","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib27","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR t cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104969_bib28","first-page":"3563","article-title":"Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma","volume":"5","author":"Crombie","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104969_bib29","unstructured":"CTCAE). version 4.03 2010 [ 2025-03-18;. Available from: \u3008https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40\u3009."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104969_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of frailty on outcomes after chimeric antigen receptor t cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant. Cell. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-Cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104969_bib32","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjh.19302","article-title":"Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMM-1 trial eligibility criteria: a real-world multicentre study","volume":"204","author":"Dima","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104969_bib33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00432-024-05765-8","article-title":"Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed\/refractoy large B-cell lymphoma: findings from a German monocentric study","volume":"150","author":"Eigendorff","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104969_bib34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjh.19505","article-title":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): a real-world IFM study from the DESCAR-T registry","volume":"205","author":"Ferment","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104969_bib35","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S1470-2045(13)70568-0","article-title":"Risk of CNS dissemination in extranodal lymphomas","volume":"15","author":"Ferreri","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104969_bib36","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104969_bib37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104969_bib38","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104969_bib39","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104969_bib40","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jha2.1043","article-title":"Fluctuation of physical function during chimeric antigen receptor T-cell therapy during rehabilitation intervention: Real-world data and risk factor analyses","author":"Hamada","year":"2024","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib41","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104969_bib42","first-page":"1514","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US myeloma immunotherapy consortium real world experince","volume":"109","author":"Hashmi","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104969_bib43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2020.10371","article-title":"Behavioral counseling interventions to prevent sexually transmitted infections: updated evidence report and systematic review for the US preventive services task force","volume":"324","author":"Henderson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2025.104969_bib44","unstructured":"Higgins Jea Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023) 2023 [;. Available from: \u3008www.training.cochrane.org\/handbook\u3009."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104969_bib45","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-Cell outcomes in large B-Cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104969_bib46","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleuel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104969_bib47","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104969_bib48","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1111\/jcmm.17550","article-title":"Predictors of response to axicabtagene-ciloleucel CAR t cells in aggresive b cell lymphomas: a real-world study","volume":"26","author":"Iovino","year":"2022","journal-title":"J. Cell. Mol. Med."},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104969_bib49","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib50","doi-asserted-by":"crossref","first-page":"581.e581","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large b cell lymphoma in the united tates","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant. Cell. Ther."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104969_bib51","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104969_bib52","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","article-title":"Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience","volume":"8","author":"Kalariya","year":"2024","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.18810","article-title":"CAR t in patients with large B-cell lymphoma not fit for autologous transplant","volume":"202","author":"Kuhnl","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104969_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-Cell therapy for relapsed\/refractory large b cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009525","article-title":"Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy","volume":"12","author":"Larue","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104969_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release sydrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104969_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104969_bib59","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood.2023023447","article-title":"Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104969_bib60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib61","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.19152","article-title":"Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function","volume":"204","author":"Mamlouk","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104969_bib62","article-title":"Prognostic value of the albumin-bilirubin grade for the prediction of post-hepatectomy liver failure: a systematic reviw and meta-analysis","author":"Marasco","year":"2011","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104969_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104969_bib64","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"HemaSphere"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104969_bib66","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104969_bib67","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104969_bib68","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104969_bib69","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib70","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.19521","article-title":"Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma","volume":"205","author":"Othman","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104969_bib71","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104969_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5114\/biolsport.2022.104916","article-title":"Body composition adaptations to lower-body plyometric training: a systematic review and meta-analysis","volume":"39","author":"Ramirez-Campillo","year":"2022","journal-title":"Biol. Sport"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104969_bib73","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104969_bib74","article-title":"Association of Interleukin-6 genetic polymorphisms (rs1800795, -174C > G and rs1800796, -572G > C) with risk of essential hypertension in the Chinese populatin","volume":"15","author":"Ren","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104969_bib75","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.ymthe.2025.03.061","article-title":"How to democratize cell and gene therapy: a global approach","volume":"33","author":"Rouce","year":"2025","journal-title":"Mol. ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.critrevonc.2025.104969_bib76","doi-asserted-by":"crossref","unstructured":"Ryan C.E., Zon R.L., Redd R., Fisher D.C., Shouval R., Kumar A., et al. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. 2023;203(5):774-780. \u3008https:\/\/doi.org\/10.1111\/bjh.19037\u3009.","DOI":"10.1111\/bjh.19037"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib77","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-Cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104969_bib79","first-page":"1403","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lacet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104969_bib80","doi-asserted-by":"crossref","unstructured":"Schwarzer G., Chemaitelly H., Abu-Raddad L.J., R\u00fccker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. 2019;10(3):476-483. \u3008https:\/\/doi.org\/10.1002\/jrsm.1348\u3009.","DOI":"10.1002\/jrsm.1348"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104969_bib81","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","article-title":"Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/curroncol32010002","article-title":"Real-world characterization of toxicities and medication management in recipients of CAR T-cell therapy for relapsed or refractory large B-cell lymphoma in Nova Scotia, Canada","volume":"32","author":"Shaw","year":"2024","journal-title":"Curr. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104969_bib83","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/cancers15174334","article-title":"The Dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-Cell lymphoma referred for CD19-Directed CAR T-Cell therapy in the Netherlands","volume":"15","author":"Spanjaart","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104969_bib84","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104969_bib85","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","article-title":"A multicenter Real-life prospective study of axicabtagene ciloleucel versus tisagenleceucel toxicity and outcomes in large B-cell lymphomas","volume":"5","author":"Stella","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104969_bib86","doi-asserted-by":"crossref","first-page":"w30186","DOI":"10.4414\/SMW.2022.w30186","article-title":"Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland","volume":"152","author":"Stolz","year":"2022","journal-title":"Swiss Med. Wkly."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib87","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jcyt.2022.03.009","article-title":"Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor t cell therapy in patients with large b cell lymphoma","volume":"24","author":"Sun","year":"2022","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104969_bib88","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ejh.14331","article-title":"Distance to CAR-T treatment center does not impede delivery","volume":"114","author":"Tan","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib89","doi-asserted-by":"crossref","first-page":"573.e571","DOI":"10.1016\/j.jtct.2023.06.018","article-title":"Negative prognostic impact of High-dose or long-term corticosteroid use in ptients with relapsed or refractory B-Cell lymphoma who received tisagenlecleucel","volume":"29","author":"Terao","year":"2023","journal-title":"Transplant. Cell. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104969_bib90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/biomedicines13010036","article-title":"Outcomes of idecabtagene vicleucel therapy in patients with Relapsed\/Refractory multiple myeloma: a Single-Institution experience","volume":"13","author":"Trando","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib91","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ajh.27381","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: a multicenter study","volume":"99","author":"Tun","year":"2024","journal-title":"Am. J. hemaology"},{"key":"10.1016\/j.critrevonc.2025.104969_bib92","doi-asserted-by":"crossref","unstructured":"Wang Y., Jain P., Locke F.L., Maurer M.J., Frank M.J., Munoz J.L., et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. 2023;41(14):2594-2606. \u300810.1200\/jco.22.01797\u3009.","DOI":"10.1200\/JCO.22.01797"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104969_bib93","first-page":"995","volume":"44","author":"Wen","year":"2019","journal-title":"Burkitt\u2019S. Lymphoma Involv. Mult. Horm. Prod. Organs FDG PET\/CT"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104969_bib94","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and Non-Relapse mortality following CAR t therapy in myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transplant. Cell. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104969_bib95","first-page":"1363","article-title":"[Tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma: real-world data from single institute experience]","volume":"63","author":"Yagi","year":"2022","journal-title":"[Rinsho ketsueki] Jpn. J. Clin. Hematol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104969_bib96","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2217\/imt-2021-0084","article-title":"Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study","volume":"13","author":"Yuen","year":"2021","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104969_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008553","article-title":"Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed\/refractory central nervous system lymphoma: a multicenter retrspective analysis of patients in China","volume":"12","author":"Yu","year":"2024","journal-title":"J. Immunother. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:44:35Z","timestamp":1773153875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":97,"alternative-id":["S1040842825003579"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104969","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104969"}}